Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases

Abstract

Background: Golgi protein-73 (GP73) is a newly identified candidate serum marker for liver diseases. The utility of this biomarker remains limited, largely due to the lack of quantitative information. The aims of this study were to quantify serum GP73 (sGP73) in healthy individuals and in patients with liver diseases, and to validate sGP73 as a biomarker for early diagnosis of liver disease. Methods: Recombinant GP73 was used to generate monoclonal (mAb) and polyclonal antibodies ( pAb). Using these antibodies in a quantitative enzyme-linked immunosorbent assay, GP73 was measured in serum from 263 patients with various forms of liver and other diseases. Results: The median sGP73 in patients with liver disease was significantly higher (P , 0.001) than in healthy individuals and in patients with other diseases. When sGP73 was used to detect liver disease, it had a sensitivity of 82% and a specificity of 80% at the optimal cut-off value of 85.5 mg/L. The area under the receiver-operating characteristic curve was 0.9. Conclusion: sGP73 concentration in patients with liver disease was three-fold higher than in healthy individuals. However, sGP73 concentrations did not differ significantly between patients from each liver disease group. Furthermore, sGP73 was not significantly elevated in patients with diseases other than liver disease compared with healthy individuals. These results suggest that sGP73 may be used as a serum marker for the diagnosis of liver disease.

Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas

“…23 Despite high concordance of our findings with regard to results and conclusions, Gu et al measured approximately 100-fold lower absolute sGOLPH2 concentrations. This discrepancy is most likely due to methodological differences.…”

Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases

“…Figure 4c shows that sGP73 rose nearly two-fold from the healthy condition (median 48.4 lg/L) to hepatitis (median 73.65 lg/L), gradually to the maximum of 153.8 lg/L (in Child C of LC), indicating continuous liver injury contributes to the elevation of sGP73, in accordance with results on tissue and serum levels. 12,[14][15][16]30 Stimulation of various etiologies, liver parenchymal cells regeneration, and quiescent stellate cells activation and proliferation followed the increase on subcellular Golgi apparatus involved in protein processing and classifying 27 ; meanwhile injury induced an upregulation of endoprotease, 31 and large amounts of GP73 were secreted into blood following furin-mediated proteolytic cleavage of its N-terminus, 32 in parallel with the fibrosis stage. The difference of our result when compared to others was a higher sGP73 levels in LC than in HCC group, maybe causing by the differences of the degree of fibrosis or inflammation of the subjects among various studies.…”

“…Gu et al in China has developed a sandwich enzyme-linked immunosorbent assay (ELISA) for quantifying GP73 in serum. 16 In spite of the significant difference between liver and non-liver diseases, they found no obvious elevation of sGP73 in HCC compared to other liver diseases.…”

Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma

“…By contrast, enzyme-linked immunosorbent assay (ELISA) is quantitative and convenient. Although a number of studies have demonstrated higher levels of sGP73 measured by ELISA in HCC than in liver cirrhosis (19)(20)(21), no significant difference in sGP73 concentrations between HCC and cirrhosis groups was identified by other studies (22)(23)(24), and in a number of studies, the sGP73 level was even lower in HCC than in liver cirrhosis (15,25). Considering the small sample size of these studies, further evaluation of ELISA-measured sGP73 in large-scale studies is required to clarify its diagnostic value in HCC.…”